查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1475205

全球風濕病治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Rheumatology Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

全球風濕病治療市場需求預計將從 2023 年的 492.1 億美元達到 2032 年近 651.1 億美元的市場規模，2024-2032 年研究期間複合年成長率為 3.16%。

風濕病治療是指用於管理和治療風濕性疾病的藥物和治療，包括影響關節、肌肉、骨骼和結締組織的自體免疫疾病、發炎和退化性疾病。這些療法旨在減輕疼痛、發炎、僵硬和關節損傷，減緩疾病進展，改善身體功能，並提高風濕性疾病患者的生活水準。

市場動態

類風濕性關節炎(RA)、系統性紅斑狼瘡(SLE)、骨關節炎(OA) 以及其他自體免疫和發炎性疾病的發生率不斷上升，推動了對風濕病治療的需求，因為患者尋求有效的治療方法來緩解症狀、減緩疾病進展並增強療效。隨著人口老化、遺傳傾向和環境因素造成全球風濕病負擔，人們越來越需要針對潛在疾病機制、調節免疫反應並恢復受影響個體的組織穩態的創新療法。

此外，生物製藥研究、免疫學和分子生物學的進步使得新型生物製劑、小分子抑制劑和標靶療法的開發成為可能，與傳統的緩解疾病的抗風濕藥物 (DMARD) 和非類固醇類抗發炎藥（NSAID）。此外，隨著製藥公司、生物技術新創公司和學術研究人員合作識別患者亞群、對疾病表現型進行分層並開發個人化治療演算法，以最佳化治療結果並最大限度地減少風險，對精準醫學、生物標記發現和藥物基因組學的日益重視推動了風濕病治療市場的創新 不利影響。

此外，風濕病領域擴大採用生物相似藥、生物優越劑和下一代療法，推動了市場競爭、定價動態和創新治療的獲取，為藥物開發商、醫療保健提供者和患者創造了機會和挑戰。然而，來自生物相似藥替代品和監管障礙的日益激烈的競爭可能會挑戰未來幾年風濕病治療市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球風濕病治療市場的各個細分市場進行了包容性評估。風濕病治療產業的成長和趨勢為這項研究提供了整體方法。

市場區隔

風濕病治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按藥物類別

  • 疾病修飾抗風濕藥物 (Dmards)（合成疾病修飾抗風濕藥物、生物疾病修飾抗風濕藥物）
  • 非類固醇類抗發炎藥（Nsaids）
  • 皮質類固醇
  • 降尿酸藥物
  • 其他

按疾病適應症

  • 類風濕關節炎
  • 骨關節炎
  • 痛風
  • 銀屑病關節炎
  • 僵直性脊椎炎
  • 其他

依給藥途徑

  • 腸外途徑
  • 口頭途徑
  • 專題

按配銷通路

  • 醫院藥房
  • 零售藥房
  • 網路藥房

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲風濕病治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。風濕病治療市場的主要參與者包括默克公司、艾伯維公司、百時美施貴寶公司、輝瑞公司、武田製藥有限公司、安進公司、基因泰克公司、諾華公司、強生創新醫學、F. Hoffmann -La Roche AG、賽諾菲。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法論
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：風濕病治療 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按藥品類別分類的市場吸引力分析
    • 依疾病適應症進行的市場吸引力分析
    • 按給藥途徑進行的市場吸引力分析
    • 按配銷通路分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球風濕病治療市場分析：依藥物類別

  • 按藥物類別概述
  • 歷史和預測數據
  • 按藥物類別分析
  • 疾病修飾抗風濕藥物 (DMARD)（合成疾病修飾抗風濕藥物、生物疾病修飾抗風濕藥物）
  • 非類固醇類抗發炎藥 (NSAID)
  • 皮質類固醇
  • 降尿酸藥物
  • 其他

第 6 章：全球風濕病治療市場分析：依疾病適應症

  • 按疾病適應症概述
  • 歷史和預測數據
  • 按疾病指徵分析
  • 類風濕關節炎
  • 骨關節炎
  • 痛風
  • 銀屑病關節炎
  • 僵直性脊椎炎
  • 其他

第 7 章：全球風濕病治療市場分析：依給藥途徑

  • 依給藥途徑概述
  • 歷史和預測數據
  • 依給藥途徑分析
  • 腸外途徑
  • 口頭途徑
  • 專題

第 8 章：全球風濕病治療市場分析：按分銷管道

  • 配銷通路概述
  • 歷史和預測數據
  • 按配銷通路分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第 9 章：全球風濕病治療市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 10 章：風濕病治療公司的競爭格局

  • 風濕病治療市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 11 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Merck & Co. Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • AbbVie Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Bristol-Myers Squibb Company
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Pfizer Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Takeda Pharmaceutical Company Limited
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Amgen Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Genentech Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Novartis AG
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Johnson & Johnson Innovative Medicine
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • F. Hoffmann-La Roche AG
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Sanofi
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR112114346

The global demand for Rheumatology Therapeutics Market is presumed to reach the market size of nearly USD 65.11 Billion by 2032 from USD 49.21 Billion in 2023 with a CAGR of 3.16% under the study period 2024 - 2032.

Rheumatology therapeutics refers to medications and treatments for managing and treating rheumatic diseases, encompassing autoimmune, inflammatory, and degenerative conditions affecting the joints, muscles, bones, and connective tissues. These therapeutics aim to alleviate pain, inflammation, stiffness, and joint damage, slow disease progression, improve physical function, and improve the standard of living for patients with rheumatic disorders.

MARKET DYNAMICS

The rising incidence of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), osteoarthritis (OA), and other autoimmune and inflammatory conditions drives the demand for rheumatology therapeutics as patients seek effective treatments that alleviate symptoms, slow disease progression, and enhance the quality of life. With aging populations, genetic predisposition, and environmental factors contributing to the global burden of rheumatic diseases, there is a growing need for innovative therapeutics that target underlying disease mechanisms, modulate immune responses, and restore tissue homeostasis in affected individuals.

Additionally, advancements in biopharmaceutical research, immunology, and molecular biology enable the development of novel biologics, small molecule inhibitors, and targeted therapies that offer improved efficacy, safety, and tolerability profiles compared to conventional disease-modifying anti-rheumatic drugs (DMARDs) and nonsteroidal anti-inflammatory drugs (NSAIDs). Moreover, the increasing emphasis on precision medicine, biomarker discovery, and pharmacogenomics drives rheumatology therapeutics market innovation as pharmaceutical companies, biotech startups, and academic researchers collaborate to identify patient subgroups, stratify disease phenotypes, and develop personalized treatment algorithms that optimize therapeutic outcomes and minimize adverse effects.

Furthermore, the growing adoption of biosimilars, biosuperiors, and next-generation therapeutics in rheumatology drives market competition, pricing dynamics, and access to innovative treatments, creating opportunities and challenges for drug developers, healthcare providers, and patients. However, increasing competition from biosimilar alternatives and regulatory hurdles may challenge the rheumatology therapeutics market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of rheumatology therapeutics. The growth and trends of rheumatology therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the rheumatology therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Disease Modifying Anti-Rheumatic Drugs (Dmards) (Synthetic Disease Modifying Anti-Rheumatic Drugs, Biologic Disease Modifying Anti-Rheumatic Drugs)
  • Nonsteroidal Anti-Inflammatory Drugs (Nsaids)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

By Disease Indication

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Gout
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Others

By Route Of Administration

  • Parenteral Route
  • Oral Route
  • Topical

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Rheumatology Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Rheumatology Therapeutics market include Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Amgen, Inc., Genentech, Inc., Novartis AG, Johnson & Johnson Innovative Medicine, F. Hoffmann-La Roche AG, Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. RHEUMATOLOGY THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Disease Indication
    • 3.7.3 Market Attractiveness Analysis By Route of Administration
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

  • 5.1. Overview By Drug Class
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Drug Class
  • 5.4. Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Historic and Forecast Sales By Regions
  • 5.5. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Historic and Forecast Sales By Regions
  • 5.6. Corticosteroids Historic and Forecast Sales By Regions
  • 5.7. Uric Acid Drugs Historic and Forecast Sales By Regions
  • 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DISEASE INDICATION

  • 6.1. Overview By Disease Indication
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Disease Indication
  • 6.4. Rheumatoid Arthritis Historic and Forecast Sales By Regions
  • 6.5. Osteoarthritis Historic and Forecast Sales By Regions
  • 6.6. Gout Historic and Forecast Sales By Regions
  • 6.7. Psoriatic Arthritis Historic and Forecast Sales By Regions
  • 6.8. Ankylosing Spondylitis Historic and Forecast Sales By Regions
  • 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1. Overview By Route of Administration
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Route of Administration
  • 7.4. Parenteral Route Historic and Forecast Sales By Regions
  • 7.5. Oral Route Historic and Forecast Sales By Regions
  • 7.6. Topical Historic and Forecast Sales By Regions

8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1. Overview By Distribution Channel
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Distribution Channel
  • 8.4. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 8.5. Retail Pharmacy Historic and Forecast Sales By Regions
  • 8.6. Online Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE RHEUMATOLOGY THERAPEUTICS COMPANIES

  • 10.1. Rheumatology Therapeutics Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF RHEUMATOLOGY THERAPEUTICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Merck & Co. Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. AbbVie Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Bristol-Myers Squibb Company
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Pfizer Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Takeda Pharmaceutical Company Limited
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Amgen Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Genentech Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Novartis AG
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Johnson & Johnson Innovative Medicine
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. F. Hoffmann-La Roche AG
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Sanofi
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class (USD MN)
  • Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Market Sales By Geography (USD MN)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Uric Acid Drugs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Disease Indication (USD MN)
  • Rheumatoid Arthritis Market Sales By Geography (USD MN)
  • Osteoarthritis Market Sales By Geography (USD MN)
  • Gout Market Sales By Geography (USD MN)
  • Psoriatic Arthritis Market Sales By Geography (USD MN)
  • Ankylosing Spondylitis Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Parenteral Route Market Sales By Geography (USD MN)
  • Oral Route Market Sales By Geography (USD MN)
  • Topical Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Rheumatology Therapeutics Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Rheumatology Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Rheumatology Therapeutics Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Disease Indication
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class (USD MN)
  • Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Market Sales By Geography (USD MN)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Uric Acid Drugs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Disease Indication (USD MN)
  • Rheumatoid Arthritis Market Sales By Geography (USD MN)
  • Osteoarthritis Market Sales By Geography (USD MN)
  • Gout Market Sales By Geography (USD MN)
  • Psoriatic Arthritis Market Sales By Geography (USD MN)
  • Ankylosing Spondylitis Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Parenteral Route Market Sales By Geography (USD MN)
  • Oral Route Market Sales By Geography (USD MN)
  • Topical Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.